Published in Transplantation on October 15, 2007
Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature (2009) 2.79
Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev (2011) 1.29
Prolonged exposure to sphingosine 1-phosphate receptor-1 agonists exacerbates vascular leak, fibrosis, and mortality after lung injury. Am J Respir Cell Mol Biol (2010) 1.27
Synthetic analogs of FTY720 [2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol] differentially regulate pulmonary vascular permeability in vivo and in vitro. J Pharmacol Exp Ther (2009) 1.11
Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci (2012) 1.09
Lyase to live by: sphingosine phosphate lyase as a therapeutic target. Expert Opin Ther Targets (2009) 1.02
Sphingosine 1-phosphate chemical biology. Biochim Biophys Acta (2008) 0.93
Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nat Rev Urol (2011) 0.86
Down-regulation of S1P1 receptor surface expression by protein kinase C inhibition. J Biol Chem (2009) 0.85
The immunosuppressant FTY720 (fingolimod) enhances glycosaminoglycan depletion in articular cartilage. BMC Musculoskelet Disord (2011) 0.83
Immunomodulatory drug FTY720 induces regulatory CD4(+)CD25(+) T cells in vitro. Clin Exp Immunol (2009) 0.82
FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. Clinics (Sao Paulo) (2013) 0.80
Lymphatic disorders after renal transplantation: new insights for an old complication. Clin Kidney J (2015) 0.79
A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia. Anticancer Drugs (2016) 0.76
Effect of FTY720 (fingolimod) on graft survival in renal transplant recipients: a systematic review protocol. BMJ Open (2016) 0.76
Novel sphingosine-1-phosphate receptor modulator KRP203 combined with locally delivered regulatory T cells induces permanent acceptance of pancreatic islet allografts. Transplantation (2013) 0.75
Benefits versus risks of latest therapies in multiple sclerosis: a perspective review. Ther Adv Drug Saf (2012) 0.75
A Stability-Indicating HPLC Method for the Determination of Fingolimod in Pharmaceutical Dosage Forms. Sci Pharm (2014) 0.75
Fingolimod Associated Bilateral Cystoid Macular Edema-Wait and See? Int J Mol Sci (2016) 0.75
FTY720 ameliorates renal fibrosis by simultaneously affecting leukocyte recruitment and TGF-β signaling in fibroblasts. Clin Exp Immunol (2017) 0.75
Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med (2005) 7.83
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Costimulation blockade with belatacept in renal transplantation. N Engl J Med (2005) 4.86
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med (2015) 4.78
Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int (2013) 3.00
Comparison between creatinine and cystatin C-based GFR equations in renal transplantation. Nephrol Dial Transplant (2007) 2.94
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet (2011) 2.82
Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant (2009) 2.27
Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial. Am J Kidney Dis (2011) 2.27
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol (2009) 2.08
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant (2004) 1.93
Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis (2005) 1.92
A novel approach to investigation of the pathogenesis of active minimal-change nephrotic syndrome using subtracted cDNA library screening. J Am Soc Nephrol (2002) 1.85
Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf) (2008) 1.79
Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol (2013) 1.74
Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study. Lancet (2008) 1.73
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation (2016) 1.68
Acute renal infarction: a case series. Clin J Am Soc Nephrol (2012) 1.68
Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study. Nephrol Dial Transplant (2012) 1.61
The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol (2007) 1.60
Sirolimus interferes with iron homeostasis in renal transplant recipients. Transplantation (2006) 1.55
Low molecular weight phenotype of Apo(a) is a risk factor of corticosteroid-induced osteonecrosis of the femoral head after renal transplant. J Rheumatol (2007) 1.50
Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol (2013) 1.50
Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int (2012) 1.47
Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation (2003) 1.46
Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens (2008) 1.42
Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. Am J Hum Genet (2006) 1.41
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol (2009) 1.40
The living kidney donor: giving life, avoiding harm. Nephrol Dial Transplant (2003) 1.40
Immature myeloid and plasmacytoid dendritic cells infiltrate renal tubulointerstitium in patients with lupus nephritis. Mol Immunol (2007) 1.39
Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients. Transplantation (2011) 1.39
Acute phase reaction to gadolinium-DTPA in dialysis patients. Nephrol Dial Transplant (2008) 1.39
The Italian experience of the national registry of renal biopsies. Kidney Int (2004) 1.38
Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation (2008) 1.34
Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol (2010) 1.31
Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis (2011) 1.27
Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am J Nephrol (2007) 1.24
Short- and long-term donor outcomes after kidney donation: analysis of 601 cases over a 35-year period at Japanese single center. Transplantation (2009) 1.20
Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood (2004) 1.20
Extra-cellular release and blood diffusion of BART viral micro-RNAs produced by EBV-infected nasopharyngeal carcinoma cells. Virol J (2010) 1.18
Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics (2009) 1.16
A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation (2003) 1.13
Renal transplantation from extended criteria cadaveric donors: problems and perspectives overview. Transpl Int (2007) 1.13
Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer (2012) 1.12
Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation (2011) 1.12
c-mip impairs podocyte proximal signaling and induces heavy proteinuria. Sci Signal (2010) 1.12
Risk factors and outcome of focal and segmental glomerulosclerosis recurrence in adult renal transplant recipients. Nephrol Dial Transplant (2005) 1.11
B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation (2008) 1.09
The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol Dial Transplant (2011) 1.09
The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: a review. Saudi J Kidney Dis Transpl (2009) 1.06
Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol (2005) 1.04
Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression. Transpl Int (2008) 1.04
Acute renal allograft rejections with major interstitial oedema and plasma cell-rich infiltrates: high gamma-interferon expression and poor clinical outcome. Nephrol Dial Transplant (2004) 1.03
Robotic assisted kidney transplantation: an initial experience. J Urol (2002) 1.02
Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit. Clin Infect Dis (2008) 1.01
The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant Rev (Orlando) (2011) 1.00
Truncation of C-mip (Tc-mip), a new proximal signaling protein, induces c-maf Th2 transcription factor and cytoskeleton reorganization. J Exp Med (2003) 1.00
Increase of proliferating renal progenitor cells in acute tubular necrosis underlying delayed graft function. Transplantation (2008) 0.98
Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. Nephrol Dial Transplant (2004) 0.98
Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol (2008) 0.97
Renal transplantation in patients with sarcoidosis: a French multicenter study. Clin J Am Soc Nephrol (2010) 0.97
Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin. J Am Soc Nephrol (2004) 0.96
BMP-2 induces a profibrotic phenotype in adult renal progenitor cells through Nox4 activation. Am J Physiol Renal Physiol (2012) 0.96
Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen. Head Neck (2013) 0.96
Management and outcome of living kidney grafts with multiple arteries. Surg Today (2005) 0.96
Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transpl Int (2012) 0.95
Interleukin-2 receptor antagonist induction in modern immunosuppression regimens for renal transplant recipients. Transpl Int (2006) 0.95
Worldwide distribution of glomerular diseases: the role of renal biopsy registries. Nephrol Dial Transplant (2009) 0.94
Recent approaches to the pathogenesis of minimal-change nephrotic syndrome. Nephrol Dial Transplant (2003) 0.94
Dialysis-related systemic microinflammation is associated with specific genomic patterns. Nephrol Dial Transplant (2007) 0.93
Consistent high concentration of the viral microRNA BART17 in plasma samples from nasopharyngeal carcinoma patients--evidence of non-exosomal transport. Virol J (2013) 0.93
Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats. Am J Physiol Renal Physiol (2009) 0.93
Glomerular lesions in patients with sickle cell disease. Medicine (Baltimore) (2010) 0.93
Telmisartan inhibits human urological cancer cell growth through early apoptosis. Exp Ther Med (2010) 0.92
Endoscopic resection for the diagnosis of visceral Kaposi's sarcoma. J Gastroenterol (2005) 0.92
ApoB C7623T polymorphism predicts risk for steroid-induced osteonecrosis of the femoral head after renal transplantation. J Orthop Sci (2007) 0.92
Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev (2015) 0.91
Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation (2010) 0.91
Comparing measures of cystatin C in human sera by three methods. Am J Nephrol (2008) 0.91
Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum (2005) 0.91
Recurrence from primary and secondary glomerulopathy after renal transplant. Transpl Int (2012) 0.91
Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. Eur J Immunol (2010) 0.90
Biomarkers as a tool for management of immunosuppression in transplant patients. Ther Drug Monit (2010) 0.90
Immunopathogenesis of idiopathic nephrotic syndrome. Contrib Nephrol (2011) 0.90
alpha- and beta-Adducin polymorphisms affect podocyte proteins and proteinuria in rodents and decline of renal function in human IgA nephropathy. J Mol Med (Berl) (2009) 0.90
Combination analysis of three polymorphisms for predicting the risk for steroid-induced osteonecrosis of the femoral head. J Orthop Sci (2008) 0.89
Can donor implantation renal biopsy predict long-term renal allograft outcome? Am J Nephrol (2007) 0.89
The role of hyperparathyroidism, erythropoietin therapy, and CMV infection in the failure of arteriovenous fistula in hemodialysis. Kidney Int (2003) 0.89
IgA nephropathy: the presence of familial disease does not confer an increased risk for progression. Am J Kidney Dis (2006) 0.89
Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation (2008) 0.89
High pretransplant serum levels of CXCL9 are associated with increased risk of acute rejection and graft failure in kidney graft recipients. Transpl Int (2009) 0.88
NF-kappa B p65 antagonizes IL-4 induction by c-maf in minimal change nephrotic syndrome. J Immunol (2004) 0.87
AQP5 is expressed in type-B intercalated cells in the collecting duct system of the rat, mouse and human kidney. Cell Physiol Biochem (2011) 0.87
The regulatory/cytotoxic graft-infiltrating T cells differentiate renal allograft borderline change from acute rejection. Transplantation (2007) 0.87
Coagulation cascade activation causes CC chemokine receptor-2 gene expression and mononuclear cell activation in hemodialysis patients. J Am Soc Nephrol (2005) 0.87
FTIR and XPS study of Pt nanoparticle functionalization and interaction with alumina. Langmuir (2008) 0.87
Sirolimus and proteinuria in renal transplant patients: evidence for a dose-dependent effect on slit diaphragm-associated proteins. Transplantation (2011) 0.87